Vertex Pharma Q1 2025 Filing: Financial Snapshot

Ticker: VRTX · Form: 10-Q · Filed: May 6, 2025 · CIK: 875320

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

Related Tickers: VRTX

TL;DR

Vertex Pharma filed its Q1 2025 10-Q, showing financial details as of March 31, 2025.

AI Summary

Vertex Pharmaceuticals Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's filing details its financial position, including common stock, additional paid-in capital, and retained earnings as of December 31, 2023, and March 31, 2024. Specific revenue figures and net income for the first quarter of 2025 and 2024 are not explicitly detailed in this header information.

Why It Matters

This filing provides a snapshot of Vertex Pharmaceuticals' financial health and structure as of early 2025, which is crucial for investors and analysts assessing the company's stability and growth trajectory.

Risk Assessment

Risk Level: low — This filing is a standard quarterly report and does not contain immediate red flags or significant negative news.

Key Numbers

Key Players & Entities

FAQ

What is Vertex Pharmaceuticals' primary business segment?

Vertex Pharmaceuticals' primary business segment is related to 'Product' sales, as indicated by the 'us-gaap:ProductMember' tag.

What was the filing date for this 10-Q report?

The filing date for this 10-Q report was May 6, 2025.

What is the fiscal year end for Vertex Pharmaceuticals?

Vertex Pharmaceuticals' fiscal year ends on December 31.

What is the company's SIC code?

The Standard Industrial Classification (SIC) code for Vertex Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.

What is the reported period for this 10-Q filing?

The conformed period of report for this 10-Q filing is March 31, 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding VERTEX PHARMACEUTICALS INC / MA (VRTX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing